$GILD

44 stories mentioning GILDUpdated 25d ago

Every FINWIRES story that references GILD, newest first.

What are analysts saying about GILD?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on GILD?

Sector Update: Health Care Stocks Decline Late Afternoon

Health care stocks were softer late Thursday afternoon, with the NYSE Health Care Index and the State Street Health Care Select Sector SPDR ETF (XLV) each decreasing 0.7%.The iShares Biotechnology ETF (IBB) dropped 1.3%.In corporate news, Abbott Laboratories (ABT) lowered its full-year earnings outlook on Thursday to reflect the acquisition of cancer diagnostics company Exact Sciences, while the healthcare firm reported Q1 results above market estimates. Its shares fell past 5%.Gilead Sciences (GILD) could beat Q1 consensus estimates, but weaker-than-expected persistence rates for Yeztugo point to a potential risk to long-term peak sales for the HIV pre-exposure prophylaxis drug, RBC Capital Markets said in a note. Gilead shares were down 0.8%.QuidelOrtho (QDEL) shares tumbled 28%. The company said late Wednesday it expects preliminary unaudited revenue of $615 million to $620 million for Q1. Analysts polled by FactSet expect $677.8 million.Hims & Hers Health (HIMS) shares jumped past 12% after a senior US health official signaled plans to ease restrictions on certain peptides.

$ABT$GILD$HIMS$QDEL

Sectors150d ago

Sector Update: Health Care

Health care stocks declined late Thursday afternoon, with the NYSE Health Care Index and the State Street Health Care Select Sector SPDR ETF (XLV) each decreasing 0.7%.The iShares Biotechnology ETF (IBB) dropped 1.4%.In corporate news, Gilead Sciences (GILD) could beat Q1 consensus estimates, but weaker-than-expected persistence rates for Yeztugo point to a potential risk to long-term peak sales for the HIV pre-exposure prophylaxis drug, RBC Capital Markets said in a note. Gilead shares were down 0.9%.

$GILD

Wire150d ago

Gilead Sciences' HIV Drug Shows Weaker-Than-Expected Persistence Nine Months After Launch, RBC Says

Gilead Sciences (GILD) could beat Q1 consensus estimates, but weaker-than-expected persistence rates for Yeztugo point to a potential risk to long-term peak sales for the HIV pre-exposure prophylaxis drug, RBC Capital Markets said in a Wednesday note.Nine months after Yeztugo's launch, RBC analysts examined third-party prescription trends to assess persistence rates, repeat dosing frequency, and broader pre-exposure prophylaxis market growth and switching dynamics.Taking into account data variability and a likely shifting capture rate, initial persistence for the drug appears to be at or below the 70% figure cited in the firm's recent doctor checks, the analysts said.Gilead's core HIV business will continue to provide a solid foundation for the stock's valuation, according to the note.The analysts said they expect continued declines in the company's hepatitis C business, but sustainable patient volumes should still contribute more than $12 billion in cash flows over the next decade.RBC maintained its sector perform rating on the stock and its price target of $123.Price: $138.51, Change: $-1.26, Percent Change: -0.90%

$GILD

Wire153d ago

Citigroup Adjusts Gilead Sciences PT to $165 From $156, Maintains Buy Rating

Gilead Sciences (GILD) has an average rating of overweight and mean price target of $160.44, according to analysts polled by FactSet.Price: $138.65, Change: $-0.38, Percent Change: -0.27%

$GILD

Showing 41-44 of 44

Track with the FINWIRES app suite

FolioX

Track GILD in your portfolio

WheelAI

Analyze GILD options with the wheel strategy

StockInsider

See market sentiment on GILD